RLYB

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Wall Street analysts forecast RLYB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLYB is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rallybio Corp revenue for the last quarter amounts to 212.00K USD, decreased -29.10 % YoY.

Rallybio Corp. EPS for the last quarter amounts to 0.36 USD, decreased -238.46 % YoY.

Rallybio Corp (RLYB) has 25 emplpoyees as of December 15 2025.

Today RLYB has the market capitalization of 30.92M USD.